Novartis preps Kisqali for FDA; Ventyx cuts 20% of workers; Keytruda plus Lenvima hits PhIII setback
Plus news about Rigel Pharmaceuticals collaborating with MD Anderson.
Novartis updates PhIII data for Kisqali: The company has already filed the NATALEE data with the EMA and will submit updated data to the FDA by the end of the year. Kisqali is currently approved in the metastatic disease setting.
Ventyx slashes 20% of workforce: The company ended September with 99 full-time employees and around $56 million in cash. The move is expected to cost the biotech $2 million in severance and related employee benefits. In November, the company cut its psoriasis program on the back of lackluster Phase II results, prompting a steep drop in its share price $VTYX.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.